Overview of US Patent 5,607,669
US Patent 5,607,669 was granted on March 4, 1997, to Abbott Laboratories. It claims a method for treating bacterial infections using a specific class of antibiotics. The patent primarily covers a patented method for administering tetracycline derivatives, focusing on a novel formulation designed to enhance bioavailability and reduce resistance.
Scope of Patent Claims
Claim Types & Scope
The patent contains independent claims that broadly cover:
- A method for treating bacterial infections comprising administration of tetracycline derivatives with specific chemical modifications.
- Specific dosage regimes, including the method of administering the compound over a particular time frame.
- Formulations involving the antibiotic in combination with carriers or excipients that facilitate targeted delivery or stability.
Key Claim Highlights
- Claim 1: Covers a method involving oral administration of a tetracycline derivative with specific R-groups that improve pharmacokinetics.
- Claim 2: Details a regiment involving dosing at particular intervals (e.g., twice daily) to optimize efficacy.
- Claims 3-5: Cover formulations, such as capsules and suspensions, with specified excipients.
Claim Limitations
- The claims are limited to tetracycline derivatives with particular chemical modifications.
- The patent emphasizes oral administration and compositional formulation aspects.
- It does not explicitly cover other routes (e.g., intravenous) or other classes of antibiotics beyond tetracyclines.
Patent Landscape & Litigation
Patent Family & Related Patents
The patent is part of a family comprising:
- Canadian Patent 2,236,035
- European Patent EP 0 714 702 B1
- Japanese Patent JP 4-768961
These filings are directed at similar chemical variants and delivery methods, creating broad coverage in multiple jurisdictions.
Patent Expiry & Term
- Expiration: The patent expired on March 4, 2014, 20 years after grant, assuming maintenance fees were paid.
- Given the expiration, the patent is now in the public domain, allowing free use of the claims.
Infringement & Litigation
No major litigation or enforcement actions related to US Patent 5,607,669 appear in publicly available legal records. However, the patent landscape for tetracycline derivatives involves extensive patenting, with multiple companies holding overlapping patents, which could lead to future patent disputes regarding formulations and indications.
Competitive Landscape
Post-expiry, generic manufacturers have introduced biosimilar or generic versions of tetracycline derivatives, focusing on optimizing formulations for resistant strains or improved pharmacokinetics. Entities such as Sandoz, Amneal, and Mylan have marketed generic tetracyclines.
Patentability and Innovation Status
Prior Art & Novelty
- The patent’s claims on specific chemical modifications of tetracyclines built upon prior art dating back to the 1950s.
- The novelty lies in the particular substitutions that confer improved bioavailability or reduced resistance.
Obviousness & Non-Obviousness
- The described modifications are considered non-obvious at the time of patent filing due to specific pharmacological improvements over earlier tetracyclines.
- Prior art, including earlier tetracycline formulations, likely limited the scope of patentability, but the specific chemical modifications are sufficiently inventive.
Legal Challenges
- As the patent has expired, no active patent rights are enforceable.
- During active years, potential invalidity challenges could have centered on prior art references showing similar modifications.
Implications for R&D & Investment
- The expired patent allows manufacturers to develop generics or biosimilars without infringement risks.
- Current R&D interest may shift towards newer antibiotics or delivery methods, given the age of this patent.
- Patent landscapes around tetracyclines are crowded, with numerous overlapping patents, reducing the attractiveness of further patenting in this space.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
5,607,669 |
| Filing Date |
July 26, 1995 |
| Grant Date |
March 4, 1997 |
| Expiry Date |
March 4, 2014 |
| Assignee |
Abbott Laboratories |
| Patent Family |
3 related patents in Canada, Europe, Japan |
| Valid Claims |
Coverage of tetracycline derivatives with specific modifications and methods of use |
| Enforcement |
No known current enforcement; expired in 2014 |
Key Takeaways
- The patent has broad claims on chemical modifications of tetracyclines and use methods, specifically oral administration.
- It is expired, removing patent barriers for generic development, leading to increased competition.
- The patent landscape for tetracyclines involves extensive overlapping patents, with ongoing development focusing on resistance and pharmacokinetics.
- No recent litigation or enforcement efforts are associated with this patent.
- The patent’s limited scope around specific derivatives and formulations could have been vulnerable to inventive step challenges but ultimately was granted based on pharmacological benefits.
FAQs
Q1: Are the claims in US Patent 5,607,669 still enforceable?
A1: No, the patent expired in 2014, making its claims unenforceable.
Q2: Can generic companies now produce tetracycline derivatives covered by this patent?
A2: Yes, since the patent expired, generics can be produced without infringement risk.
Q3: What was the core inventive concept of this patent?
A3: The chemical modification of tetracycline derivatives to improve bioavailability and reduce resistance, as well as specific administration methods.
Q4: Are there active patents similar to 5,607,669?
A4: Numerous patents exist around tetracyclines, with some overlapping claims but many are expired or are in different jurisdictions.
Q5: How does this patent fit into the current landscape for antibiotics?
A5: It is part of the older generation of tetracycline patents; the industry has shifted focus towards newer classes due to resistance issues and regulatory developments.
References
[1] US Patent 5,607,669, “Method for Treatment of Bacterial Infections,” Abbott Laboratories, granted March 4, 1997.
[2] European Patent EP 0 714 702 B1.
[3] Canadian Patent CA 2,236,035.
[4] Japanese Patent JP 4-768961.
